| Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ... The Lancet 379 (9829), 1893-1901, 2012 | 1003 | 2012 |
| Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors I Krop, T Demuth, T Guthrie, PY Wen, WP Mason, P Chinnaiyan, ... Journal of clinical oncology 30 (19), 2307-2313, 2012 | 343 | 2012 |
| BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance GS Falchook, JC Trent, MC Heinrich, C Beadling, J Patterson, CC Bastida, ... Oncotarget 4 (2), 310, 2013 | 157 | 2013 |
| Postcesarean analgesia with both epidural morphine and intravenous patient-controlled analgesia: neurobehavioral outcomes among nursing neonates B Wittels, B Glosten, EAM Faure, AH Moawad, M Ismail, J Hibbard, ... Anesthesia & Analgesia 85 (3), 600-606, 1997 | 139 | 1997 |
| Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436) GS Falchook, GV Long, R Kurzrock, KB Kim, HT Arkenau, MP Brown, ... Clinical Cancer Research 20 (17), 4449-4458, 2014 | 69 | 2014 |
| Opioid antagonist adjuncts to epidural morphine for postcesarean analgesia: maternal outcomes B Wittels, B Glosten, EAM Faure, AH Moawad, M Ismail, J Hibbard, ... Anesthesia & Analgesia 77 (5), 925-932, 1993 | 61 | 1993 |
| The identification and characterization of oligodendrocyte thromboxane A2 receptors SC Blackman, G Dawson, K Antonakis, GC Le Breton Journal of Biological Chemistry 273 (1), 475-483, 1998 | 58 | 1998 |
| Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation‐positive tumors D Ouellet, KF Grossmann, G Limentani, N Nebot, K Lan, L Knowles, ... Journal of pharmaceutical sciences 102 (9), 3100-3109, 2013 | 57 | 2013 |
| Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic … DA Bershas, D Ouellet, DB Mamaril-Fishman, N Nebot, SW Carson, ... Drug Metabolism and Disposition 41 (12), 2215-2224, 2013 | 48 | 2013 |
| Identification and functional characterization of thromboxane A2 receptors in Schwann cells N Muja, SC Blackman, GC Le Breton, GH DeVries Journal of neurochemistry 78 (3), 446-456, 2001 | 45 | 2001 |
| Assessment of the drug interaction potential and single‐and repeat‐dose pharmacokinetics of the BRAF inhibitor dabrafenib AB Suttle, KF Grossmann, D Ouellet, LE Richards‐Peterson, G Aktan, ... The Journal of Clinical Pharmacology 55 (4), 392-400, 2015 | 44 | 2015 |
| Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation‐positive solid tumors CL Denton, E Minthorn, SW Carson, GC Young, LE Richards‐Peterson, ... The Journal of Clinical Pharmacology 53 (9), 955-961, 2013 | 43 | 2013 |
| Toxicology screening in adolescent trauma S GORDON, WC TOEPPER, SC BLACKMAN Pediatric emergency care 12 (1), 36-39, 1996 | 38 | 1996 |
| Forehead swelling caused by Pott's puffy tumor in a 9-year-old boy with sinusitis. SC Blackman, MR Schleiss Pediatrics International 47 (6), 2005 | 37 | 2005 |
| Emergence and compartmentalization of fatal multi-drug-resistant cytomegalovirus infection in a patient with autosomal-recessive severe combined immune deficiency SC Blackman, NS Lurain, DP Witte, AH Filipovich, P Groen, MR Schleiss Journal of pediatric hematology/oncology 26 (9), 601-605, 2004 | 32 | 2004 |
| Accelerating pediatric cancer drug development: challenges and opportunities for pediatric master protocols T Khan, M Stewart, S Blackman, R Rousseau, M Donoghue, K Cohen, ... Therapeutic Innovation & Regulatory Science 53 (2), 270-278, 2019 | 28 | 2019 |
| Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with … ADJ Pearson, K Stegmaier, F Bourdeaut, G Reaman, D Heenen, ... European Journal of Cancer 139, 135-148, 2020 | 21 | 2020 |
| Phase I clinical trial of an allosteric AKT inhibitor, MK-2206, using a once weekly (QW) dose regimen in patients with advanced solid tumors. A Biondo, TA Yap, L Yan, A Patnaik, I Fearen, RD Baird, ... Journal of Clinical Oncology 29 (15_suppl), 3037-3037, 2011 | 20 | 2011 |
| Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature SC Blackman, AR Evenson, SD Voss, CE Barnewolt, M Puder Fetal diagnosis and therapy 24 (2), 119-125, 2008 | 18 | 2008 |
| RAF inhibitor dabrafenib (GSK2118436) is active in melanoma brain metastases, multiple BRAF genotypes and diverse cancers GS Falchook, GV Long, R Kurzrock, KB Kim, HT Arkenau, MP Brown, ... Lancet 379 (9829), 1893, 2012 | 15 | 2012 |
Razelle Kurzrock, MDProfessor of Medicine, Medical College of WisconsinVerified email at mcw.edu
